Literature DB >> 15499178

CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.

Satoshi Yamaori1, Hiroshi Yamazaki, Shunsuke Iwano, Kazuma Kiyotani, Keiko Matsumura, Goro Honda, Kazuko Nakagawa, Takashi Ishizaki, Tetsuya Kamataki.   

Abstract

The purpose of this study was to evaluate a contribution of polymorphic cytochrome P450 (CYP) 3A5 to the oxidation of diltiazem, midazolam and testosterone by liver microsomes from Japanese subjects. Twenty-seven liver samples were classified into three groups according to the CYP3A5 genotypes; CYP3A5(*)1/(*)1 (n=3), (*)1/(*)3 (n=12) and (*)3/(*)3 (n=12). The results of genotyping and immunochemical quantitation of CYP3A5 protein showed a good accordance between the CYP3A5 genotype and CYP3A5 content but not CYP3A4 content in liver microsomes. The expression levels of hepatic CYP3A5 protein ranged from 20 to 60% of the sum of CYP3A4 and CYP3A5 contents in subjects with at least one wild type allele ((*)1). The CYP3A5 contents correlated well with liver microsomal activities of diltiazem N-demethylation, midazolam 1'- and 4-hydroxylations and testosterone 6beta-hydroxylation among subjects carrying at least one (*)1 allele. In addition, the correlation coefficients of CYP3A5 contents with the rates of diltiazem N-demethylation, midazolam 1'-hydroxylation and testosterone 6beta- hydroxylation were higher than those of CYP3A4, although the value of CYP3A5 with the midazolam 4-hydroxylation rate was similar to that of CYP3A4. Kinetic analyses revealed a biphasic diltiazem N-demethylation in liver microsomes from subjects carrying the (*)1 allele. The apparent V(max)/K(m) values for recombinant CYP3A5 indicated the greater contributions to diltiazem N-demethylation and midazolam 1'-hydroxylation as compared with CYP3A4. These results suggest that polymorphic CYP3A5 contributes markedly to the drug oxidations, particularly diltiazem N-demethylation, midazolam 1'- hydroxylation and testosterone 6beta-hydroxylation by liver microsomes from Japanese subjects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15499178     DOI: 10.2133/dmpk.19.120

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  10 in total

1.  Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate.

Authors:  Goutam Chowdhury; Norie Murayama; Yusuke Okada; Yasuhiro Uno; Makiko Shimizu; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

Review 2.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation.

Authors:  Martin F Fromm; Helmut Schwilden; Iouri Bachmakov; Jörg König; Frank Bremer; Jürgen Schüttler
Journal:  Eur J Clin Pharmacol       Date:  2007-09-05       Impact factor: 2.953

4.  Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles.

Authors:  Hiroshi Yamazaki; Minako Nakamoto; Makiko Shimizu; Norie Murayama; Toshiro Niwa
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

5.  Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.

Authors:  M A Perera; R K Thirumaran; N J Cox; S Hanauer; S Das; C Brimer-Cline; V Lamba; E G Schuetz; M J Ratain; A Di Rienzo
Journal:  Pharmacogenomics J       Date:  2008-09-30       Impact factor: 3.550

6.  Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5.

Authors:  Yusuke Okada; Norie Murayama; Chihiro Yanagida; Makiko Shimizu; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Drug Metab Dispos       Date:  2008-10-23       Impact factor: 3.922

7.  Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms.

Authors:  Junyan Wang; Lingfei Huang; Peng Gao; Yan Hu; Yinghua Ni; Zhengyi Zhu; Liwen Zhang; Jufei Yang; Huifen Zhang; Luo Fang
Journal:  Eur J Clin Pharmacol       Date:  2020-08-15       Impact factor: 2.953

8.  Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.

Authors:  Yoshiyuki Shirasaka; Shu-Ying Chang; Mary F Grubb; Chi-Chi Peng; Kenneth E Thummel; Nina Isoherranen; A David Rodrigues
Journal:  Drug Metab Dispos       Date:  2013-05-30       Impact factor: 3.922

9.  CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes.

Authors:  Maho Okubo; Norie Murayama; Makiko Shimizu; Tsutomu Shimada; F Peter Guengerich; Hiroshi Yamazaki
Journal:  J Toxicol Sci       Date:  2013       Impact factor: 2.196

Review 10.  Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.

Authors:  Junji Saruwatari; Takateru Ishitsu; Kazuko Nakagawa
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.